Quantitative electroencephalography as a potential biomarker in migraine
Brain and Behavior · 2023-12 · 13 (12)
DOI: 10.1002/brb3.3282 ↗At a glance
Journal article in Brain and Behavior, published online on 2023-10-10. Written by Suk Jae Kim and 2 co-authors. Institution: Samsung Smart Neurology Clinic, Cheonan, Chungcheongnam-do, South Korea. Major MEDLINE topics: Electroencephalography, Migraine Disorders. Cited 10 times so far (Crossref); 42 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Objective
The aim of this study was to investigate the utility of quantitative electroencephalography (QEEG) as a diagnostic tool for migraine and as an indicator of treatment response by comparing QEEG characteristics between migraine patients and controls, and monitoring changes in these characteristics alongside clinical symptoms in response to treatment Background We hypothesized that patients with migraine exhibit distinctive characteristics in QEEG measurements, which could be used as potential diagnostic biomarkers and as a tool for monitoring treatment response.
Methods
A total of 720 patients were included in the study, comprising 619 patients with migraine and 101 subjects as a control group. QEEG measurements were analyzed for absolute power across specific frequency bands: delta wave (0.5–4 Hz), theta wave (4–8 Hz), alpha wave (8–12 Hz), beta wave (12–25 Hz), and high beta wave (25–30 Hz). The absolute power was normalized against a normative dataset from NeuroGuide, with electrodes being highlighted for significance if they exceeded 1.96. Clinical symptoms were also monitored for correlation with QEEG changes.
Results
Our analysis showed that patients with migraine exhibited significantly higher absolute power across all frequencies, most markedly within the high beta frequency range. When considering electrodes with z ‐scores exceeding the threshold of 1.96 in the high beta range, a significant association with migraine diagnosis was observed (per 1 electrode increase, OR 1.06; 95% CI 1.01–1.11; p = .012). Moreover, pre‐ and posttreatment changes in QEEG measurements corresponded with changes in clinical symptoms.
Conclusion
Patients with migraine have distinctive QEEG measurements, particularly regarding absolute power and the number of electrodes that surpassed the z ‐score threshold in high beta wave activity. These findings suggest the potential of QEEG as a diagnostic biomarker and as a tool for monitoring treatment response in migraine patients, warranting further large‐scale studies for confirmation and expansion.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Samsung Smart Neurology Clinic, Cheonan, Chungcheongnam-do, South Korea.
- PE Research Lab, SK Hynix Inc., Icheon, Gyeonggi-do, South Korea.
- Department of Neurology, Chungnam National University College of Medicine, Chungnam National University Hospital, Daejeon, South Korea.
ORCID profiles: Suk Jae Kim
Cite
APA
Kim, S. J., Yang, K., & Kim, D. (2023). Quantitative electroencephalography as a potential biomarker in migraine. Brain and Behavior, 13(12). https://doi.org/10.1002/brb3.3282
Vancouver
Kim SJ, Yang K, Kim D. Quantitative electroencephalography as a potential biomarker in migraine. Brain and Behavior. 2023;13(12). doi:10.1002/brb3.3282
BibTeX
@article{Kim2023,
author = {Kim, Suk Jae and Yang, Kyungjin and Kim, Daeyoung},
title = {Quantitative electroencephalography as a potential biomarker in migraine},
journal = {Brain and Behavior},
year = {2023},
volume = {13},
number = {12},
doi = {10.1002/brb3.3282}
}
EUVIMED